The federal agency joins a community of health experts who think smoking is not a good way to consume weed. The commissioner of the Food and Drug Administration, Scott Gottlieb, recently suggested that the agency would never approve of smoking cannabis. This opposition to smoking is shared by many health experts, even those who approve of medical cannabis in general. FEATURED PHOTO: WASHINGTON, D.C. – APRIL 05: FDA Commissioner-designate Scott Gottlieb testifies during a Senate Health, Education, Labor and Pensions Committee hearing on April 5, 2017 on Capitol Hill in Washington, D.C. (Photo by Zach Gibson/Getty Images)
Cannabidiol (CBD), a compound derived from the cannabis plant that does not produce a “high” and has been an increasing focus of medical research, was shown in a new large-scale, randomized, controlled trial to significantly reduce the number of dangerous seizures in patients with a severe form of epilepsy called Lennox–Gastaut syndrome. In the new study comparing 2 doses of CBD to a placebo, the researchers reported a 41.9 percent reduction in “drop seizures”—a type of seizure that results in severe loss of muscle control and balance—in patients taking a 20 mg/kg/d CBD regimen, a 37.2 percent reduction in those on a 10 mg/kg/d CBD regimen, and a 17.2 percent reduction in a group given a placebo.
While a Food and Drug Administration advisory panel recently recommended pharmaceutical-grade cannabidiol (CBD) as a treatment for two rare forms of epilepsy, CBD medication is not the same thing as medical marijuana, which is more available than ever before and promoted for wide variety of health conditions. The American Epilepsy Society (AES) wants to alert the 3 million people with epilepsy about the myths and facts related to CBD medication – derived from one of the many compounds found in in cannabis (the marijuana plant) – and medical marijuana. Medical marijuana, which is now legal in 29 states as well as the District of Columbia, refers to the physician-prescribed use of the whole, unprocessed marijuana plant or its basic extracts to treat the symptoms of an illness and othe...
Photo: Jaelah Jerger (L) and Vala Jerger (R) (Photo courtesy their mother.) Indiana allows CBD oil for epilepsy, but the girl’s particular form of epilepsy is not protected. It all began last August. Even though the laws in Indiana for cannabis are strict, the Jergers knew there were certain laws permitting CBD oil use for epilepsy patients. Concerned about the side-effects of antiepileptic drug Keppra, they decided to try CBD oil to help with their daughter Jaelah’s seizures, ordering it from a company in Colorado. Then, unexpectedly, Child Protective Services showed up at their door.
Michigan, Texas and many other states are looking at doing what the Texas Department of State Health is thinking about; a crackdown on foods and oils which contain CBD. CBD is a component in marijuana/hemp plants. Unlike THC, the psychedelic active ingredient in cannabis, it cannot actually get you high; it’s frequently utilized to deal with seizure disorders. Texas and other states are proposing a crack down on merchants who sell items consisting of “CBD”, stop selling of illegal and “unapproved” products. Many such over the counter CBD hemp oils have been found to be harmful due to lack of control in manufacturing, dangerous content and filler. CBD and all marijuana products are still illegal under federal law in all states, however CBD crackdowns...
Cannabidiol (CBD) oil has become the hot new product in states that have legalized medical marijuana. The non-intoxicating marijuana extract is being credited with helping treat a host of medical problems — everything from epileptic seizures to anxiety to inflammation to sleeplessness.
Cannabidiol oil comes from the marijuana plant, but it contains only trace amounts, if any, of the compound that produces a high. While cannabidiol oil has no psychoactive effects, it may relieve pain, and it shows some promise as a treatment for migraines. More research is needed to determine whether cannabidiol (CBD) oil is safe and effective. Also, because products derived from the marijuana, or cannabis, plant tend to be unregulated, it is difficult to ensure the quality and quantity of ingredients.
For pediatric-onset treatment-resistant epilepsy, cannabinoids are effective as an adjunctive treatment for reducing seizure frequency by 50 percent or more, according to a review published online March 6 in the Journal of Neurology, Neurosurgery & Psychiatry. More effective than placebo for reducing seizure frequency, achieving seizure freedom.
While they are similar in some ways, there are important differences between hemp oil and CBD oil. As a consumer, it’s easy to get confused by phrases such as “cannabis oil” and “marijuana oil,” especially when many companies seem to use these terms interchangeably. Let’s take a closer look at hemp oil and CBD oil to learn how to distinguish the two. Hemp and marijuana are cousins in the plant world. Hemp oil and CBD oil come from different strains of the Cannabis sativa plant. However, hemp oil contains low levels of CBD – typically less than 25 parts per million – while CBD oil can be up to 15% CBD. Because the plants are related, some unscrupulous sellers of hemp oil are trying to market it for its medicinal value, which is negligible.
Cannabidiol is an effective and generally well-tolerated add-on treatment for drop seizures in patients with Lennox-Gastaut syndrome, according to research published in The Lancet. “Patients with Lennox-Gastaut syndrome, a rare, severe form of epileptic encephalopathy, are frequently treatment resistant to available medications,” Elizabeth A. Thiele, MD, from the pediatric epilepsy program at Massachusetts General Hospital, and colleagues wrote. “No controlled studies have investigated the use of cannabidiol for patients with seizures associated with Lennox-Gastaut syndrome.”
New data in The Lancet provides further support for GW Pharma’s drug, Epidiolex, for the treatment of a rare form of epilepsy. GW Pharmaceuticals has achieved encouraging Phase III results for Epidiolex, which have been published in leading scientific journal, The Lancet. The company’s lead candidate is being developed for the treatment of epilepsy – a condition characterized by the abnormal firing of neurons in the brain, leading to seizures. In particular, the company targets Lennox-Gastaut syndrome, a rare, lifelong form of epilepsy, which causes significant developmental delays.
Scientists in Israel are conducting open clinical trials utilizing whole plant cannabis in search of an autism spectrum disorder treatment after stumbling upon a tremendous observation in an unrelated study. Bonni Goldstein M.D., resident Marijuana.com medical expert and published author, said the early evidence shows autism is a result of genetic mutations and a deficit in the endocannabinoid system. Goldstein noted, “one case report and numerous anecdotal reports [have revealed] that cannabinoids may help some children with this disorder have better communication, less repetitive behaviors, less anxiety, and better social interaction.”